CPA Platform in Oncology
Various Cancers
DevelopmentActive
Key Facts
About InnoSIGN
InnoSIGN is a private, pre-revenue diagnostics platform company developing a proprietary bioinformatics solution for disease interpretation. Its Comprehensive Pathway Analysis (CPA) platform uses a proprietary algorithm to analyze RNA-sequencing data, inferring the activity of key cell signaling pathways to provide deeper, actionable insights beyond single mutations. The platform is positioned to support the full drug development continuum, from preclinical research to companion diagnostics, primarily in oncology but also in autoimmune and metabolic diseases. The company seeks to address the industry's reliance on single biomarkers by offering a systems-level view of disease mechanisms.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology/Immuno-oncology Portfolio | MSD | Phase III/Commercial |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| LADR Platform | LadRx | Preclinical |
| NK Cell Stimulation (via JadiCell) | Therapeutic Solutions International | Preclinical |
| Zip-Code Library for Oncology | Kodikaz Therapeutic Solutions | Pre-clinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| Max Access Solutions (with The Max Foundation) | Tanner Pharma Group | N/A (Donation/Distribution Program) |
| Oncology Services | Transcure Bioservices | Preclinical |
| SBX 2021 | Stramsen Biotech | Early-stage Clinical |